SCIG Hizentra denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for scig hizentra are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna May Issue a "Not FDA-Approved" Denial for Hizentra

This denial type — when applied to Hizentra — is almost always a classification or coding error. Hizentra (immune globulin 20%, subcutaneous) holds FDA approval for specific indicated conditions. However, Aetna may generate this denial if the claim is submitted under a diagnosis code that falls outside the labeled indications, if there is a mismatch between the J-code or NDC submitted and the product Aetna recognizes, or if the plan is attempting to deny an off-label use of the product for a condition not listed in the FDA approval.

## Why This Denial Is Appealable

If the prescribed use matches an FDA-approved indication, the denial is factually incorrect and should be overturned on appeal with appropriate documentation. If the use is off-label, the appeal must demonstrate that the use is supported by authoritative medical literature, recognized compendia, and the applicable specialty society guideline — and that it meets Aetna's own criteria for coverage of off-label drug use.

## Federal Appeal Framework

• Internal appeal (Level 1): File promptly. Include the FDA approval documentation and the prescribing label. If this is an on-label denial, cite the FDA-approved indication directly.
• External review (ACA §2719 / ERISA §503): If internal appeal fails, request IRO review within 4 months of the final denial. An IRO can independently assess whether the use aligns with FDA approval or recognized clinical standards.
• Expedited review: Available if clinical urgency exists — simultaneous internal and external review, with a 72-hour response requirement.

## Documentation to Gather

1. FDA labeling confirmation — a copy of the current FDA-approved prescribing information for Hizentra, with the applicable indication highlighted. 2. Diagnosis-to-indication mapping — a clear written statement from the prescriber showing that the patient's confirmed diagnosis falls within the labeled indication. 3. Coding verification — confirm the J-code, NDC, and diagnosis (ICD-10) codes submitted on the claim match the product and indication exactly. 4. Off-label support (if applicable) — if the use is off-label, gather references from recognized medical compendia and the applicable specialty society guideline organization supporting the use. 5. Prescriber letter — addressing the specific denial reason and correcting any factual mischaracterization of the FDA approval status.

## Criteria-Mapping Strategy

Obtain Aetna's published medical policy for immunoglobulin therapy and compare its coverage criteria against the FDA label. Match each policy requirement to a specific piece of clinical documentation. If Aetna's policy incorrectly describes the FDA approval status, cite the FDA label page and date directly in the appeal letter.